

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68, 1/70, C12P 19/34, C07H 21/04		(11) International Publication Number: WO 96/40996
(21) International Application Number: PCT/US96/08429		(43) International Publication Date: 19 December 1996 (19.12.96)
(22) International Filing Date: 3 June 1996 (03.06.96)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(30) Priority Data: 08/480,220 7 June 1995 (07.06.95) US		
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		
(72) Inventors: BIRKENMEYER, Larry; 5303 W. Leland, Chicago, IL 60630 (US). MUSHAHWAR, Isa, K.; 18790 Arbor Boulevard, Grayslake, IL 60030 (US).		
(74) Agents: POREMBSKI, Priscilla, E. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		
(54) Title: METHOD FOR DETECTING NUCLEIC ACID SEQUENCES USING COMPETITIVE AMPLIFICATION		
(57) Abstract <p>The present invention provides a method for quantitatively detecting the amount of a target nucleic acid sequence which may be present in a test sample. A test sample which may contain a target nucleic acid sequence comprising target sequences X and Y is contacted with two primer sets, the first set being specific for target X and the second set being specific for target Y. The test sample also is contacted at the same time with an internal standard sequence IS, which is substantially derived from a combination of the first and second target sequences, and its corresponding oligonucleotide primers. Haptens are associated with the oligonucleotide primer sets in such a way that amplified target sequence products X and Y are detected by capture on a solid phase to which anti-hapten capture reagents are attached. A signal ratio of (X + Y)/S is determined to quantitate the amount of the target nucleic acid sequence contained in the sample.</p>		
<div style="text-align: right;"> Applicants: Chong-Jin Oon, et al. U.S. Serial No.: 09/362,394 Filed: July 28, 1999 (Exhibit 4) </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**METHOD FOR DETECTING NUCLEIC ACID SEQUENCES
USING COMPETITIVE AMPLIFICATION**

FIELD OF THE INVENTION

5 The present invention relates to a method for amplifying and detecting a nucleic acid sequence which may be present in a test sample, and in particular, to a method for quantitatively detecting a nucleic acid sequence which may be present in a test sample.

10 **BACKGROUND OF THE INVENTION**

 Methods for amplifying a target nucleic acid sequence that may be present in a test sample are, by now, well known in the art. Such methods include the polymerase chain reaction (PCR) and ligase chain reaction (LCR). These methods have found widespread application in the medical diagnostic
15 field as well as the fields of genetics, molecular biology and biochemistry.

 In PCR, a pair of primers are employed in excess to hybridize at the outside ends of complementary strands of the target nucleic acid. The primers are each extended by a polymerase using the target nucleic acid as a template. The extension products become target sequences themselves,
20 following dissociation from the original target strand. New primers are then hybridized and extended by a polymerase, and the cycle is repeated to geometrically increase the number of target sequence molecules. PCR is disclosed in U.S. Patent Nos. 4,683,195 and 4,683,202.

 LCR is an alternative mechanism for target amplification. In
25 LCR, two sense (first and second) probes and two antisense (third and fourth) probes are employed in excess over the target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being positioned adjacent to each other so that the primary probes can be ligated into a fused
30 product. Further, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar ligatable fashion. If the target is initially double stranded, the secondary probes will also hybridize to the target complement in

the first instance. Once the fused strand of sense and antisense probes are separated from the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary fused product. The fused products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. This technique is described in EP-A-320,308, hereby incorporated by reference. Other aspects of LCR technique such as gap LCR (GLCR) are disclosed in EP-A-439,182, to K.C. Backman et al., hereby incorporated by reference.

Unfortunately, one drawback of nucleic acid amplification reactions is that they are mostly qualitative. The nature of amplification reactions makes it difficult for them to be used to quantitatively detect the presence of a target sequence which may be present in a test sample. Accordingly, while traditional amplification reactions are useful for detecting the presence of a minute quantity of a target sequence in a test sample, traditional amplification reactions generally cannot be employed to determine the quantity of a target sequence in a test sample.

Some traditional amplification reactions have been modified to enable quantitative amplification reaction analysis. One such quantitative amplification reaction is called "competitive amplification." This method is commonly applied to PCR. According to this method, a standard nucleic acid sequence competes with a target sequence during the amplification reaction. Generally, the standard sequence and a sample suspected of containing a target sequence are combined in a dilution series in which the amount of the standard sequence is constant in all members of the series. Alternatively, the standard sequence and sample sequence are combined in a dilution series in which the amount of standard sequence is varied among the members of the dilution series. In any case, the concentration of the standard sequence in the members of the dilution series is known. PCR is then performed on all members of the dilution series and results in the production of a mixture of two nucleic acid species. One species is derived from the standard sequence and one species is derived from the sample sequence. The concentration of

each species in a particular dilution depends on the number of copies of the standard and the sample sequences in the dilution prior to amplification.

During the amplification reaction, detectable groups are typically introduced into both types of sequences. After amplification, the two species are
5 separated and the amount of detectable group incorporated into each species is determined. This detection procedure is performed for each member of the dilution series. A competition curve can then be generated and the amount of sample sequence can be extrapolated based on the known amounts of standard sequence.

10 Methods of competitive amplification have been described in U.S. Patent No. 5,219,727; Jalava et al., BioTechniques 15:134-39 (1993). While these competitive amplification techniques have shown utility, they require substantial amounts of sample preparation time as well as technician interaction and concomitant risk of sample contamination. In addition,
15 performing amplification on members of a dilution series requires more reagents than performing amplification on a single sample. All of these factors add to the costs of performing competitive amplification reactions.

Moreover, all prior art methods involve PCR amplification wherein the middle part of the standard sequence is completely unrelated to
20 the target sequence to be detected, and is flanked by target-specific primers to used to differentiate the standard from the target sequence. Thus, the two sequences are easily differentiated. Such a method is incompatible with LCR amplification because the middle part of both the target and standard
25 sequences is critical to the success of the amplification reaction. No prior art method existed, prior to Applicant's invention, for differentiating a standard sequence from a target sequence using LCR amplification.

Thus, there is a need for a method of quantitatively performing an amplification reaction, wherein the middle part of the standard sequence is substantially similar to the target sequence, which does not require amplifying
30 a series of concentration standards alongside each assay to be quantitated, and can be employed in a clinical laboratory setting.

SUMMARY OF THE INVENTION

The present invention provides a method for detecting the amount of a target nucleic acid sequence which may be present in a test sample comprising the steps of:

- 5 (a) contacting said test sample with means for performing a nucleic acid amplification reaction and:
- (i) two target primer sets, wherein a first primer set represents a first target sequence and a second primer set represents a second target sequence within the
10 genome of the target nucleic acid, and wherein each primer set comprises four oligonucleotide primers of which two are sense primers and the other two are antisense primers,
- (ii) an internal standard (IS) sequence,
15 wherein the IS sequence is substantially derived from a combination of the first target sequence and the second target sequence,
- (iii) an IS primer set, wherein the IS primer set comprises four oligonucleotide primers of which two
20 are derived from the first target sequence and the other two are derived from the second target sequence, and
- (iv) a set of dNTPs,
under hybridizing conditions such that, for each pair of target oligonucleotide primer sequences or IS oligonucleotide primer
25 sequences which hybridizes to each strand of said target sequences or said IS sequence or its complementary strand, a ligase reaction takes place whereby the nucleotide gap between the oligonucleotide primer sequences is filled by the dNTPs in the presence of the target nucleic acid sequence, wherein each of the ligase reactions require the same set of dNTPs, or a subset thereof, to
30 fill the gap; and
- (b) determining the ratio of target amplification products to IS amplification products present in the test sample.

The method of the invention described above also can be used to distinguish between two different nucleic acid sequences which may be present in a test sample, particularly where one of the two nucleic acid sequences comprises a mutation or allele of the other nucleic acid sequence.

5 The invention also provides compositions for quantitatively detecting the DNA of hepatitis B virus which may be present in a sample, the composition comprising four oligonucleotide primers of from about 18 to about 25 base pairs having sequences sufficiently complementary to either a first target sequence or second target sequence within the HBV genome. Also
10 provided are compositions for distinguishing between the wildtype and mutant DNA of hepatitis B comprising codon 145 of the HBV S-gene and/or codon 28 of the HBV precore antigen gene. Test kits comprising the compositions described above also are provided by the present invention.

15 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the method of the invention which depicts target sequences X and Y and their corresponding primer sets as well as an internal standard sequence and its corresponding primer set.

20 DETAILED DESCRIPTION OF THE INVENTION

The method herein provided is applicable to nucleic acid amplification reactions (hereinafter "amplification reactions") which employ primer sets (also referred to as "probe sets") to amplify a target nucleic acid sequence. Briefly, the method uses two target primer sets, each primer set
25 representing a different target sequence within the genome of the target nucleic acid sequence, i.e., a first target sequence and a second target sequence, in an amplification reaction to quantitatively detect the concentration of a target sequence which may be present in a test sample. Additionally, the method uses an internal standard (IS) sequence which comprises a sequence
30 substantially derived from a combination of the first target sequence and the second target sequence and its corresponding IS primer set. In the method, the two target sequences and the IS sequence compete for the same

oligonucleotide primers which comprise the target and IS primer sets. The method generally comprises contacting a test sample suspected of containing a target sequence with two target primer sets, an IS sequence and its corresponding IS primer set and dNTPs under hybridizing conditions to form a reaction mixture. The reaction mixture is cycled to allow oligonucleotide primer sequences to hybridize with, and thus, amplify the corresponding target sequences or IS sequence and its complementary strand via a ligase reaction. The presence of any amplified target sequences or IS sequences can then be detected.

10 A target primer series comprises two primer sets, each set of primers representing a different target sequence within the genome of the target nucleic acid sequence. A first primer set represents a first target sequence and a second primer set represents a second target sequence. In the description of the invention, the first target sequence is referred to as "Target X" and the second target sequence is referred to as "Target Y." Each target primer set comprises four oligonucleotide primers of which two are sense primers and the other two are antisense primers.

20 The IS sequence is substantially derived from a combination of the first target sequence and the second target sequence of the target nucleic acid. As used in the method of the invention, the IS sequence can be single-stranded or double-stranded. The corresponding IS primer set also comprises four oligonucleotide primers of which two are derived from the first target sequence and the other two are derived from the second target sequence.

25 In an alternative embodiment, the method of the invention can be used to quantitatively detect only one of the two target sequences X and Y by employing the oligonucleotide primers specific for the particular target sequence to be detected, an IS sequence and its corresponding IS primer set. In the amplification reaction, the target sequence X or Y and the IS sequence compete for the same two shared oligonucleotide primers which comprise the primer sets of target sequences X or Y, respectively, and the internal standard. The other two oligonucleotide primers of the IS primer set can be any sequence which will effectively participate in LCR while at the same time

30

not interfere in the amplification of the target sequence to be detected.

A test sample is typically any component of an individual's body which can contain a target nucleic acid sequence of interest. Test samples can be prepared using methodologies well known in the art such as by taking a specimen from a patient and, if necessary, disrupting any cells contained therein to release nucleic acids.

A target nucleic acid sequence is generally a nucleic acid sequence (e.g., RNA or DNA) comprising at least two target sequences to which members of the target primer series hybridize. In the case of RNA target sequences, it will be understood that a cDNA copy of the RNA target sequence is synthesized before the amplification reaction. In a preferred embodiment of the invention, both target sequences and, thus, their corresponding primer sets characteristically are found within the genome of the target nucleic acid sequence. This feature of the invention provides the advantage of reducing the risk that the target nucleic acid sequence would not be detected in the amplification reaction due to either of the first or second target sequences being deleted or otherwise altered in the test sample. Furthermore, typically both primer sets represent target sequences that are highly conserved in the genome of the target nucleic acid to be detected. This feature of the invention provides the advantage of reducing the risk that the target nucleic acid sequence would not be detected in the amplification reaction due to the presence of a variant sequence in the test sample. For example, when the nucleic acid sequence to be detected is from a bacterial or viral genome, the primer sets should represent target sequences from those gene products which are highly conserved between bacterial strains or viral isolates, respectively.

For example, the target sequence may comprise the genome of a virus such as Hepatitis B, and the target sequences may comprise regions characteristically present in the viral genome such as the surface antigen gene, the core antigen gene and the precore antigen gene. Alternatively, both target sequences may be found within any one region of the two regions mentioned above.

In another embodiment of the invention, the two target sequences X and Y are found within different genomes. This embodiment is particularly useful for the detection of nucleic acid sequences of related organisms. For example, in an amplification reaction for the detection of
5 HIV, the first target sequence could be derived from a region of the HIV-1 genome and the second target sequence could be derived from the same region or, alternatively, from a different region of the HIV-2 genome.

The target nucleic acid sequence can be single stranded, double stranded, continuous, or fragmented so long as portions of it are sufficiently
10 continuous for the individual target primer sets to hybridize and amplify any specific target sequences. While the sequence of the entire genome of the target nucleic acid sequence may not be known, it is generally the case that at least the target sequence which comprises the target primer sets is known.

Although there is no minimum length requirement of the target
15 nucleic acid sequence to be detected in an amplification reaction, typically, each oligonucleotide primer of a primer set is composed of from about 18 to about 25 base pairs, which translates into ligated primer pairs of approximately 50 nucleotides.

A target primer series along with an IS sequence and its
20 corresponding primer set can be employed in an amplification reaction to quantitatively determine the amount of a target sequence in a test sample. Amplification reactions such as LCR and GLCR are known in the art. These reactions typically employ primers to repeatedly generate copies of a target nucleic acid sequence which is usually a small region of a much larger nucleic
25 acid sequence. Primers are themselves nucleic acid sequences that are complementary to regions of a target sequence and under suitable conditions hybridize or bind to the complementary regions of the target sequence. Copies of the target sequence are typically generated by the process of primer ligation which utilizes enzymes with ligase activity to ligate adjacent primer
30 pairs. While enzymatic methods of ligation are predominant, other methods such as, for example, chemical ligation are equally suitable for use according to the present invention. The nucleotides that are added to the primers or

probes, as monomers or preformed oligomers, are also complementary to the target sequence. Once the primers have been sufficiently ligated they are separated from the target sequence, usually by heating the reaction mixture to a "melt temperature" which is one where complementary nucleic acid strands dissociate. Thus, a sequence complementary to the target sequence is formed.

A new amplification cycle can then take place to further amplify the number of target sequences by separating any double stranded sequences, allowing primers to hybridize to their respective targets, ligating the hybridized primers and reseparating. The complementary sequences that are generated by amplification cycles can serve as templates for primer or probe extension to further amplify the number of target sequences. Hence, multiple copies of the target sequence and its complementary sequence are produced.

Generally, four primers, two of which are complementary to a portion of a target strand and the other two which are complementary to its complement, are employed in LCR. Other reagents employed in amplification reactions, collectively designated as means for performing an amplification reaction, are well known and include: enzyme cofactors such as magnesium; salts; nicotinamide adenine dinucleotide (NAD); and deoxynucleotide triphosphates (dNTPs) such as, for example, adenine triphosphate, guanine triphosphate, cytosine triphosphate and thymine triphosphate.

In the method of the invention, a reaction mixture preferably is cycled between about 15 and about 60 times, more preferably, between about 20 and about 45 times. It also should be noted that the concentrations of, for example, the nucleotide triphosphates, enzymes and cofactors employed in the instant method may be higher than those normally used in a typical amplification reaction.

After a target primer series, IS sequence and its corresponding primer set are employed in an amplification reaction, amplified target sequence products (also referred to as "target amplification products") and amplified IS sequence products (also referred to as "IS amplification products") can be detected. In one embodiment, the detection of amplified target sequence products is separated from the detection of amplified IS

sequence products into two reactions. Alternatively, in another embodiment of the invention, the detection of target amplification products and IS amplification products are determined by one detection reaction, wherein the target amplification products and IS amplification products are labeled in such a way that the two amplification products are distinguishable. For example, the target amplification products could be attached to a fluorescent label that fluoresces at one wavelength, whereas the IS amplification products are attached to a fluorescent label that fluoresces at a second wavelength. Both wavelengths could be read in one reaction mixture.

In the embodiment of the invention where two separate reactions take place, after the amplification reaction, the amplified target sequence products and amplified IS sequence products can be detected by using unique capture reagents that are immobilized to a solid phase such that each capture reagent immobilizes a unique amplified product, i.e., target sequence X, target sequence Y or IS sequence. Alternatively, in another embodiment of the invention, a first capture reagent immobilizes the target amplification products and a second capture reagent immobilizes the IS amplification products.

Capture reagents typically comprise "specific binding pair members" which can directly or indirectly form a specific binding pair with the amplified products. As used herein, specific binding member means a member of a binding pair, i.e., two different molecules where one of the molecules through, for example, chemical or physical means specifically binds to the other molecule. In addition to antigen and antibody specific binding pairs, other specific binding pairs include, but are not intended to be limited to, avidin and biotin; haptens such as adamantane and carbazole which are described in U.S. Patent Application Serial No. 08/049,888 filed April 21, 1993, published as PCT Application No. PCT/US93/05534, and U.S. Patent Application Serial No. 08/084,495 filed July 1, 1993, published as PCT/US93/06832, and antibodies specific for haptens; complementary nucleotide sequences; enzyme cofactors or substrates and enzymes; and the like. According to the embodiment being described in conjunction with

Figure 1, the capture reagent used to detect the target amplification products is different than the capture reagent used to detect the IS amplification products.

Solid phase refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid phase can be chosen for its intrinsic ability to attract and immobilize a binding member. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize a binding member. The additional receptor can include a charged substance that is oppositely charged with respect to a binding member or to a charged substance conjugated to a binding member. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid phase and which has the ability to immobilize another binding member through a specific binding reaction. The receptor molecule enables the indirect binding of a binding member to a solid phase material before the performance of the assay or during the performance of the assay. The solid phase thus can be, for example, latex, plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface or surfaces of test tubes, microtiter wells, sheets, beads, microparticles, chips, and other configurations known to those of ordinary skill in the art. It is contemplated and within the scope of the invention that the solid phase also can comprise any suitable porous material with sufficient porosity to allow, when necessary, access by a conjugate. Microporous structures are generally preferred, but materials with gel structure in the hydrated state may be used as well. The porous structure of nitrocellulose has excellent absorption and adsorption qualities for a wide variety of reagents including binding members. Nylon also possesses similar characteristics and also is suitable. Such materials may be used in suitable shapes, such as films, sheets, or plates, or they may be coated onto or bonded or laminated to appropriate inert carriers such as paper, glass, plastic films or fabrics.

There are a variety of ways in which the amplification products may be immobilized to a solid phase. For example, the solid phase may be coated with polynucleotides which form binding pairs with the amplification products. Alternatively, the amplification products may be labeled with

indirect labels which form specific binding pairs with a binding member coupled to the solid phase. It will be understood that the specific binding member coupled to the solid phase may form binding pairs with all of the amplification products that may be produced in an amplification reaction or multiple specific binding pairs coupled to the solid phase may be specific for individual amplification products, for example, target sequence X amplification products or target sequence Y amplification products. Those skilled in the art also will recognize that various methods exist and may be employed to incorporate a label into an amplification product.

After the target amplification products, if any, and IS amplification products are immobilized to the solid phase, their presence thereon can be detected using a "label." The term label refers to a molecule or moiety having a property or characteristic which is capable of detection. A label can be directly detectable, as with, for example, radioisotopes, fluorophores, chemiluminophores, enzymes, colloidal particles, fluorescent microparticles and the like; or a label may be indirectly detectable, as with, for example, specific binding members. It will be understood that direct labels may require additional components such as, for example, substrates, triggering reagents, light and the like to enable detection of the label. When indirect labels are used for detection, they are typically used in combination with a "conjugate." A conjugate is typically a specific binding member which has been attached or coupled to a directly detectable label. Coupling chemistries for synthesizing a conjugate are well known in the art and can include, for example, any chemical means and/or physical means that does not destroy the specific binding property of the specific binding member or the detectable property of the label.

Hence, where the amplified products which are immobilized to a solid phase carry a directly detectable label, the immobilized amplified products can be detected directly. In cases where the amplified products carry an indirect label, a conjugate comprising a binding member which is specific for the indirect label can be employed to detect the presence of the amplified product on the solid phase.

The different amplification products can be differentiated by labeling the various amplification products with differentiable labels. For example, each amplification product can be labeled, directly or indirectly, with distinct fluorphores which emit light at different wavelengths.

5 Alternatively, each amplification product can be labeled with a different enzyme each of which emits a signal in the presence of a different fluorogenic substrate. As a further alternative, the amplification products can be differentiated based upon the timing at which the labels produce a signal. Specifically, the signal from a fluorophore and enzyme can be differentiated
10 by reading a constant signal from the fluorophore and reading a rate signal from the enzyme whereby the constant signal, if any, establishes a baseline signal from which the rate signal begins. Such a detection method has been described in co-pending U.S. Patent Application Serial No. 08/362,036 filed December 22, 1994, which enjoys common ownership and is incorporated
15 herein by reference.

According to one embodiment of the invention, and with reference to Figure 1, a test sample which may contain a target nucleic acid sequence comprising target sequences X and Y is contacted with two primer sets, the first set being specific for target X and comprising oligonucleotide
20 primers 1, 2, 3 and 4, the second set being specific for target Y and comprising oligonucleotide primers 5, 6, 7 and 8. The test sample also is contacted at the same time with an internal standard sequence IS and its corresponding oligonucleotide primers 1, 2, 5 and 6. Haptens A, B and C are associated with the oligonucleotide primer sets in such a way that amplified
25 target sequence products X and Y are detected by capture on microparticles to which anti-hapten antibody capture reagents are attached. In the embodiment depicted in Figure 1, amplification products X and Y are captured by anti-B antibody and a signal is generated with a mixture of anti-A antibody and anti-C antibody conjugated with a label, for example, the enzyme alkaline
30 phosphatase. Similarly, IS amplification products are captured by anti-A antibody and a signal is generated with anti-C antibody conjugated with a label such as alkaline phosphatase. A signal ratio of $(X + Y)/S$ is determined to

quantitate the amount of the target nucleic acid sequence contained in the sample.

In accordance with the underlying principles of the method of the invention, in the absence of X and Y target sequences, or in the presence of low levels, the degree of IS target amplification should remain constant. As the starting concentration of X and Y target sequences increases, the four oligonucleotide primers involved in IS amplification will compete for the same sequences as those for X and Y target amplification, since the same four nucleotide primers are involved in X and Y target amplification. Thus, the final level of IS amplification will progressively decrease as the starting concentration of X and Y target sequences progressively increases.

During the course of amplification, hybrid structures may form between target amplification products and IS amplification products. Such hybrids cannot participate in ligation, even though oligonucleotides with 3'-hydroxyl termini within such hybrids can still be extended by the DNA polymerase. Thus, as the levels of amplification products increase, there should be an increase in the formation of such hybrids. This in turn will reduce the amount of IS amplification product generated as compared to the amount that would have been generated had the first and second target sequences not been present. The method of the invention is designed so that the amount of IS sequence used in the amplification reaction is such that the hybrid formation does not significantly decrease the amount of X and Y amplification products generated over the course of the reaction.

The extent of hybrid formation in the reaction mixture is likely to include large networks of structures containing many oligonucleotides and amplification products. In the presence of X and Y target sequences, such hybrids may increase the sensitivity of target X and target Y detection since for each hybrid captured by anti-A antibody, there are two sets of haptens (i.e., B and C) which are detectable by a labeled conjugate. On the other hand, hybrid structures should not cause false positives because they cannot form in the absence of the target sequences.

The 5' to 3' exonuclease activity of DNA polymerase can

cleave the hybrid structures described above by cutting the ligated amplification product strand to which the oligonucleotide primer being extended does not hybridize. In order for the strand to be cut by the DNA polymerase, the strand must be single-stranded upstream of the cut site (i.e., 5'). Optionally, in order for the polymerase to cut the DNA, the sequence of the strand to be cut may not be modified at the 5' end. Thus, by haptenating the 5' ends of oligonucleotide primers 4 and 5, but not haptenating the 5' ends of oligonucleotide primers 1 and 8, both strands of amplified IS sequence products would be susceptible to cleavage, while both X and Y amplified sequence products would be protected from cleavage.

The net result is that IS amplification products would be cleaved, thus lowering the signal generated by the IS amplification products, while X and Y amplification products would not be cleaved, thus maintaining the signal generated by the target amplification products and allowing their participation in subsequent cycles of amplification. Cleavage would occur during cycling and afterwards by including a final incubation at or just below the T_m of nucleotide primers 2 and 7. This would result in the presence of IS amplification products in a cleavable conformation (i.e., a forked hybrid structure in which the 5'-arm of the fork is single-stranded). It will be understood that such cleavage will not occur if the polymerase used lacks 5' to 3' exonuclease activity.

In accordance with the theory of the invention, as the signal of target sequences X and Y increases through the generation of amplification products over the course of the amplification reaction and then levels off, the IS signal would start at a constant level and then decrease due to oligonucleotide primers competition, the possible formation of non-ligatable hybrids and the possible exonuclease cleavage of IS amplification products as described above.

The amount of X and Y in a test sample can be determined by locating the signal ratio of $(X+Y)/IS$ for the sample on a standard curve generated by plotting $(X+Y)/IS$ versus known starting concentrations of target sequences X and Y in the amplification reaction. By determining the ratio of

the signal generated by the target amplification products (X+Y) to the signal generated by the IS amplification products, one can derive the original amount of X and Y targets in the test sample.

5 The following examples are provided to further illustrate the present invention and are not intended to limit the scope of the invention.

EXAMPLES

EXAMPLE 1

QUANTITATIVE LCR AMPLIFICATION OF HBV

10 Two target sequences were co-amplified with an IS target sequence using GLCR amplification. One target sequence, target sequence X (SEQ ID No. 1) although presented as a single strand for simplicity, was actually used in duplex form. SEQ. ID. No. 1 corresponds to map positions 180 to 225 of the hepatitis B virus (HBV) as reported by Ono et al., Nucleic
 15 Acids Research 11:1747-57 (1983). The other target sequence, target sequence Y (SEQ ID No. 2), which also is presented as a single strand, also was employed in duplex form. SEQ ID No. 2 corresponds to map positions 658 to 703 of HBV. The insert was cloned from HBV subtype ay. Both sequences are shown below in Table 1 in a 5' to 3' direction.

20 **TABLE 1**

SEQ. ID. No.	5'-Sequence-3'
1	TAGGACCCCTGCTCGTGTTACAGGCGGGGTTTTTCTTGTTGACAAG
2	CCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAAGTGGTTC

30 A linearized double-stranded recombinant DNA plasmid Y82-1 was constructed which contained the X and Y target sequences from the vector pUC19. The HBV insert was derived from a BamHI fragment of the HBV genome, approximately 1400 base pairs long, comprising the entire surface antigen gene (S-gene), a portion of the pre-S gene and a little of the X gene.

Target-specific probes were designed to amplify and detect the above target sequences by LCR. The first primer set was specific for SEQ ID

No. 1 and its complementary strand. Two probes from this set (SEQ ID No. 3 and SEQ ID No. 4) were haptenated with biotin which is designated "Bio". The remaining two probes from this set (Seq ID No. 5 and SEQ ID No. 6) were haptenated with fluorescein which is designated "Fl". The 5' ends of SEQ ID No. 4 and SEQ ID No. 5 were functional with a phosphate group, which is designated "p", to allow ligation of SEQ ID No. 3 to SEQ ID No. 5 and ligation of SEQ ID No. 4 to SEQ ID No. 6. SEQ ID No. 4 and SEQ ID No. 6 hybridized with SEQ ID No. 1, and SEQ ID No. 3 and SEQ ID No. 5 hybridized with SEQ ID No. 1's complementary strand. The probe set employed to amplify and detect target sequence X is shown in Table 2 where individual probes are listed in a 5' to 3' direction.

TABLE 2

	SEQ. ID. No.	5'-Sequence-3'
	3	BioTAGGACCCCTGCTCGTGTTACA
15	4	pAACACGAGCAGGGGTCCTABio
	5	pCGGGGTTTTTCTTGTTGACAAGFl
	6	FICTTGTCAACAAGAAAAACCCCGCC

A second primer set was specific for SEQ ID No. 2 and its complementary strand. Two probes from this set (SEQ ID No. 7 and SEQ ID No. 8) were haptenated with adamantane which is designated "Ad". The remaining two probes from this set (Seq ID No. 9 and SEQ ID No. 10) were haptenated with fluorescein (Fl). The 5' ends of SEQ ID No. 8 and SEQ ID No. 9 were functional with a phosphate group (p) to allow ligation of SEQ ID No. 7 to SEQ ID No. 9 and ligation of SEQ ID No. 8 to SEQ ID No. 10. SEQ ID No. 8 and SEQ ID No. 10 hybridized with SEQ ID No. 2, and SEQ ID No. 7 and SEQ ID No. 9 hybridized with SEQ ID No. 2's complementary strand. The probe set employed to amplify and detect target sequence Y is shown in Table 3 where individual probes are listed in a 5' to 3' direction.

TABLE 3

	SEQ. ID. No.	5'-Sequence-3'
	7	AdCCGTTTCTCCTGGCTCAGTTTAC
35	8	pAACTGAGCCAGGAGAAACGGAd
	9	pAGTGCCATTTGTTCAAGTGGTTCFl

10 FIGAACCACTGAACAAATGGCACTA

5 An internal standard target sequence was synthesized which comprised a chimera of the 5'-half of the X sequence and the complementary strand of the 5'-half of the Y sequence. The IS target used was single-stranded. The sequence is shown below in Table 4 in a 5' to 3' direction.

TABLE 4

	SEQ. ID. No.	5'-Sequence-3'
10	11	
		TAGGACCCCTGCTCGTGTTACAGTAAACTGAGCCAGGAGAAACGG

15 The primer set specific for SEQ ID No. 11 and its complementary strand consisted of the four oligonucleotide primers SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 7 and SEQ ID No. 8.

The plasmid Y82-1, containing the X and Y target sequences as described above, was tested at eight different concentrations in the reaction, as set forth in Table 5 below, to co-amplify the target sequences according to GLCR essentially as described in EP-A-439,182. Concentrated 5X LCR buffer used in the reaction comprised 250 mM EPPS buffer, pH 7.8, 50 mM MgCl₂, 50 mM NH₄Cl, 400 mM K⁺ and 50 ug/ml bovine serum albumin (BSA). LCR "Master Solution" comprised the following components:

	Component	Final Concentration
25	34 ul dGTP (50 uM)	1 uM
	34 ul dGTP (50 mM)	1 uM
	17 ul beta-NAD (10 mM)	100 uM
	4.25 ul oligonucleotide primer SEQ ID No. 3	2.5 x 10 ¹⁰ /ul
	4.25 ul oligonucleotide primer SEQ ID No. 4	2.5 x 10 ¹⁰ /ul
30	4.25 ul oligonucleotide primer SEQ ID No. 5	2.5 x 10 ¹⁰ /ul
	4.25 ul oligonucleotide primer SEQ ID No. 6	2.5 x 10 ¹⁰ /ul
	4.25 ul oligonucleotide primer SEQ ID No. 7	2.5 x 10 ¹⁰ /ul
	4.25 ul oligonucleotide primer SEQ ID No. 8	2.5 x 10 ¹⁰ /ul
	4.25 ul oligonucleotide primer SEQ ID No. 9	2.5 x 10 ¹⁰ /ul
35	4.25 ul oligonucleotide primer SEQ ID No. 10	2.5 x 10 ¹⁰ /ul
	6.8 ul IS target sequence DNA (100 copies/ul)	20 copies/LCR
	340 ul 5X LCR buffer	
	945.2 ul H ₂ O	

The enzyme solution comprised the following components:

Component	Units/LCR
175 ul Abbott ligase (1360 units/ul)	6800
14 ul Amplitaq [®] polymerase (5 units/ul)	2
21 ul 1X LCR buffer	

The Abbott ligase is commercially available from Abbott Laboratories, Abbott Park, IL. The Amplitaq[®] polymerase is commercially available from Cetus Corporation, Emeryville, CA. 2.5 ul Y82-1 was added to 41.5 ul LCR Master Solution. The mixture was mixed and then centrifuged using a microfuge for several seconds to settle the mixture. One drop of mineral oil was added to each reaction mixture, and the mixture was heated to 100°C for three minutes and centrifuged again. The mixture was allowed to cool to 75°C, then six ul enzyme solution was added to obtain a final volume of 50 ul. Each 50 ul reaction was performed in triplicate. Thermal cycling was performed in a COY Tempcycler, commercially available from Coy Laboratory Products, Inc., Ann Arbor, MI, for 40 cycles of 85°C for 30 seconds and 54°C for 60 seconds. After thermocycling, all three replicates were combined. The combined LCR pool was divided in half and analyzed in two separate IMx assays. Each IMx assay was run in duplicate. The first IMx assay (IMx-1) was designed to detect HBV X and Y target sequences. Specifically, 35 ul of each combined LCR pool were added to 35 ul of IMx line diluent, commercially available from Abbott Laboratories. Microparticles to which anti-fluorescein antibody was attached captured the oligonucleotides which were detected with conjugate that contained a 50/50 ratio of anti-biotin antibody and anti-adamantane antibody conjugated to alkaline phosphatase (AP). The second IMx assay (IMx-2) was designed to detect the IS target sequence. Thirty-five ul of each combined LCR pool were added to 35 ul of IMx line diluent. Microparticles to which anti-biotin antibody was attached captured the oligonucleotides which were detected with conjugate that contained anti-adamantane antibody conjugated to AP. IMx results for each LCR pool are reported below.

TABLE 5

	LCR Pool No.	Y82-1 Molecules	IMx-1	IMx-2
	1	10^7	1568	49
	2	10^6	1523	206
5	3	10^5	1377	523
	4	10^4	990	778
	5	10^3	645	924
	6	10^2	398	1058
	7	10	177	1123
10	8	0	19	1180

A log:log plot of Y82-1 molecules versus the ratio of IMx-1/IMx-2 showed that the quantitation of the target nucleic acid sequence was linear over five orders of magnitude.

Example 2

Detection of Wild-Type and Mutant Forms of HBV Precore Gene and Surface Antigen Gene

The method of the invention can be used to distinguish between the wild-type (Wt) and mutant (Mut) sequences for the HBV surface antigen (HBsAg) codon 145 mutation. Codon 145 of the HBsAg gene codes for the amino acid glycine. However, a point mutation within this codon changes the amino acid to arginine, resulting in a vaccine escape phenotype. The Wt sequence (SEQ ID No. 12), although presented as a single strand for simplicity, is used in duplex form. The point mutations of the mutant sequence (SEQ ID No. 13) is presented in bold-type. Target-specific probes are designed to amplify and detect the Wt and Mut target sequences by LCR, as set forth in Table 6 below. The primer set which is specific for SEQ ID No. 12 and its complementary strand comprises SEQ ID No. 14, SEQ ID No. 15, SEQ ID No. 16 and SEQ ID No. 17. The 5' ends of SEQ ID No. 15 and SEQ ID No. 16 are functional with a phosphate group (p) to allow ligation of SEQ ID No. 14 to SEQ ID No. 16 and ligation of SEQ ID No. 15 to SEQ ID No. 17. SEQ ID No. 18 is replaced for SEQ ID No. 14 for the mutant sequence SEQ ID No. 13.

Similarly, the method of the invention can be used to detect a point mutation within codon 28 of the HBV precore antigen (HBeAg) gene. Codon 28 codes for the amino acid tryptophan. However, a point mutation within this codon changes the amino acid to a stop codon, resulting in a HBeAg-phenotype. An often-associated second mutation occurs three bases further downstream. The Wt sequence (SEQ ID No. 19), although presented as a single strand for simplicity, is used in duplex form. The point mutations of the mutant sequence (SEQ ID No. 20) are presented in bold-type. Target-specific probes are designed to amplify and detect the Wt and Mut sequences by LCR, as set forth in Table 6 below. The primer set which is specific for SEQ ID No. 19 and its complementary strand comprises SEQ ID No. 21, SEQ ID No. 22, SEQ ID No. 23 and SEQ ID No. 24. The 5' ends of SEQ ID No. 22 and SEQ ID No. 23 were functional with a phosphate group (p) to allow ligation of SEQ ID No. 21 to SEQ ID No. 23 and ligation of SEQ ID No. 22 to SEQ ID No. 24. Oligonucleotide primer SEQ ID No. 25 is replaced for primer SEQ ID No. 21 for the single point mutation.

The IS sequence is shown as SEQ ID No. 26 in Table 6 below. The primer set specific for SEQ ID No. 26 and its complementary strand comprises the four oligonucleotide primers SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 23 and SEQ ID No. 24. To perform competitive LCR for the HBsAg gene, oligonucleotides listed above for the target sequence one wishes to detect, either the Wt or Mut sequence, are used along with oligonucleotides SEQ ID No. 23 and SEQ ID No. 24. To perform competitive LCR for the HBeAg gene, oligonucleotides listed above for the target sequence one wishes to detect, either the Wt or Mut sequence, are used along with oligonucleotides SEQ ID No. 16 and SEQ ID No. 17.

Alternatively, both HBsAg and HBeAg competitive LCR assays can be performed together, preferably both Wt assays or both Mut assays together, since they share the same nucleotide requirements. In this case, the IS will always be amplified because oligonucleotide primers SEQ ID No. 16, SEQ ID No. 17, SEQ ID No. 23 and SEQ ID No. 24 will always be present. No additional dNTPs are required for gap filling on the IS because only dGTP

is required which already would be present in the other LCR assays.

TABLE 6

	SEQ. ID. No.	5'-Sequence-3'
	12	
5		CTGTACCAAACCTTCGGACGGAAATTGCACCTGTATTCCCATCCC
	13	
		CTGTACCAAACCTTCGGACAGAAATTGCACCTGTATTCCCATCCC
	14	FICTGTACCAAACCTTCGGAC
	15	pTCCGAAGGTTTGGTACAGFI
10	16	pAAATTGCACCTGTATTCCCATCCCBio
	17	BioGGGATGGGAATACAGGTGCAATTTC
	18	FICTGTACCAAACCTTCGGACA
	19	
		TGTGCCTTGGGTGGCTTTGGGGCATGGACATTGACCCTTATAAA
15	20	
		TGTGCCTTGGGTGGCTTTAGGACATGGACATTGACCCTTATAAA
	21	FITGTGCCTTGGGTGGCTTTG
	22	pAAAGCCACCCAAGGCACAFI
	23	pCATGGACATTGACCCTTATAAAAd
20	24	AdTTTATAAGGGTCAATGTCCATGCCC
	25	FITGTGCCTTGGGTGGCTTTA
	26	
		GGGATGGGAATACAGGTGCAATTCGGGCATGGACATTGACCCTTAT
25		AAA

Using the IMx format as described in Example 1, the Wt and Mut HBsAg amplification products would be captured on anti-fluorescein microparticles and detected with anti-biotin conjugate. The Wt and Mut HBeAg amplification products would be captured on anti-fluorescein particles and detected with anti-adamantane conjugate. To test for HBsAg amplification products and HBeAg amplification products in one reaction, a mixture of anti-adamantane and anti-biotin conjugate would be used. In a second IMx test, the co-amplified IS products, present in all reactions, would be captured on anti-biotin microparticles and detected with anti-adamantane conjugate. In this way, the IS products would be specifically detected and compared to the IMx signal of the target sequences being tested as described in Example 1.

23

	LCR Test	SEQ ID No.	Hapten	dNTPs Required
5	HBeAg-Wt	21, 22	Fl	G, C
		23, 24	Ad	
10	HBeAg-Mut	25, 22	Fl	G, T
		23, 24	Ad	
15	HBsAg-Wt	14, 15	Fl	G, C
		16, 17	Bio	
	HBsAg-Mut	18, 15	Fl	G, T
		16, 17	Bio	
	IS Target	23, 24	Ad	G only
		16, 17	Bio	

20 While the invention has been described in detail and with reference to specific embodiments, it will be apparent to one skilled in the art that various changes and modifications may be made to such embodiments without departing from the spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Birkenmeyer, Larry
 Mushahwar, Isa K.
- 10 (ii) TITLE OF INVENTION: METHOD FOR DETECTING NUCLEIC
 ACID SEQUENCES USING
 COMPETITIVE AMPLIFICATION
- 15 (iii) NUMBER OF SEQUENCES: 26
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Abbott Laboratories D377/AP6D
 (B) STREET: 100 Abbott Park Road
20 (C) CITY: Abbott Park
 (D) STATE: Illinois
 (E) COUNTRY: USA
 (F) ZIP: 60064-3500
- 25 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC Compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
30 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
 (B) FILING DATE:
 (C) CLASSIFICATION:
- 35 (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Porembski, Priscilla E.
 (B) REGISTRATION NUMBER: 33,207
 (C) DOCKET NUMBER: 5770.US.01
- 40 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: 708/937-6365
 (B) TELEFAX: 708/938-2623
45 (C) TELEX:

25

- (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
TAGGACCCCT GCTCGTGTTA CAGGCGGGGT TTTTCTTGT GACAAG 46
- (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
CCGTTTCTCC TGGCTCAGTT TACTAGTGCC ATTTGTTTCA TGGTTC 46
- (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' biotin
(B) LOCATION: 1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
TAGGACCCCT GCTCGTGTTA CA 22
- (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1
(ix) FEATURE:
(A) NAME/KEY: 3' biotin
(B) LOCATION: 19
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
AACACGAGCA GGGGTCCTA 19
- (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1
(ix) FEATURE:

26

(A) NAME/KEY: 3' fluorescein
(B) LOCATION: 22

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGGGGTTTTT CTTGTTGACA AG

22

(2) INFORMATION FOR SEQ ID NO:6:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: synthetic DNA

(ix) FEATURE:

(A) NAME/KEY: 5' fluorescein
(B) LOCATION: 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

20 CTTGTCAACA AGAAAAACCC CGCC

24

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(ix) FEATURE:

(A) NAME/KEY: 5' adamantane
(B) LOCATION: 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

35 CCGTTTCTCC TGGCTCAGTT TAC

23

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: synthetic DNA

(ix) FEATURE:

(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1

(ix) FEATURE:

(A) NAME/KEY: 3' adamantane
(B) LOCATION: 21

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAACTGAGCC AGGAGAAACG G

21

(2) INFORMATION FOR SEQ ID NO:9:

55 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

60 (ii) MOLECULE TYPE: synthetic DNA

(ix) FEATURE:

(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1

(ix) FEATURE:

(A) NAME/KEY: 3' fluorescein
(B) LOCATION: 22

65

- 5 (2) INFORMATION FOR SEQ ID NO:15:
5 (i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 18 base pairs
5 (B) TYPE: nucleic acid
5 (C) STRANDEDNESS: single
5 (D) TOPOLOGY: linear
10 (ii) MOLECULE TYPE: synthetic DNA
10 (ix) FEATURE:
10 (A) NAME/KEY: 5' phosphate
10 (B) LOCATION: 1
15 (ix) FEATURE:
15 (A) NAME/KEY: 3' fluorescein
15 (B) LOCATION: 18
15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
TCCGAAGGTT TGGTACAG 18
- 20 (2) INFORMATION FOR SEQ ID NO:16:
20 (i) SEQUENCE CHARACTERISTICS:
20 (A) LENGTH: 24 base pairs
25 (B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
25 (D) TOPOLOGY: linear
25 (ii) MOLECULE TYPE: synthetic DNA
25 (ix) FEATURE:
25 (A) NAME/KEY: 5' phosphate
25 (B) LOCATION: 1
30 (ix) FEATURE:
30 (A) NAME/KEY: 3' biotin
30 (B) LOCATION: 24
30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
35 AAATTGCACC TGTATTCCCA TCCC 24
- 40 (2) INFORMATION FOR SEQ ID NO:17:
40 (i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 25 base pairs
40 (B) TYPE: nucleic acid
40 (C) STRANDEDNESS: single
40 (D) TOPOLOGY: linear
45 (ii) MOLECULE TYPE: synthetic DNA
45 (ix) FEATURE:
45 (A) NAME/KEY: 5' biotin
45 (B) LOCATION: 1
45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
50 GGGATGGGAA TACAGGTGCA ATTTC 25
- 55 (2) INFORMATION FOR SEQ ID NO:18:
55 (i) SEQUENCE CHARACTERISTICS:
55 (A) LENGTH: 19 base pairs
55 (B) TYPE: nucleic acid
55 (C) STRANDEDNESS: single
55 (D) TOPOLOGY: linear
55 (ii) MOLECULE TYPE: synthetic DNA
55 (ix) FEATURE:
60 (A) NAME/KEY: 5' fluorescein
60 (B) LOCATION: 1
60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
CTGTACCAAA CCTTCGGACA 19
- 65 (2) INFORMATION FOR SEQ ID NO:19:
65 (i) SEQUENCE CHARACTERISTICS:
65 (A) LENGTH: 44 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
TGTGCCTTGG GTGGCTTTGG GGCATGGACA TTGACCCTTA TAAA
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: genomic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
TGTGCCTTGG GTGGCTTTAG GACATGGACA TTGACCCTTA TAAA
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' fluorescein
(B) LOCATION: 1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
TGTGCCTTGG GTGGCTTTG
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1
(ix) FEATURE:
(A) NAME/KEY: 3' fluorescein
(B) LOCATION: 18
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
AAAGCCACCC AAGGCACA
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' phosphate
(B) LOCATION: 1
(ix) FEATURE:
(A) NAME/KEY: 3' adamantane
(B) LOCATION: 22
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

30

CATGGACATT GACCCTTATA AA

22

(2) INFORMATION FOR SEQ ID NO:24:

- 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
10 (ii) MOLECULE TYPE: synthetic DNA
(ix) FEATURE:
(A) NAME/KEY: 5' adamantane
(B) LOCATION: 1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

15 TTTATAAGGG TCAATGTCCA TGCCC

25

(2) INFORMATION FOR SEQ ID NO:25:

- 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
25 (ix) FEATURE:
(A) NAME/KEY: 5' fluorescein
(B) LOCATION: 1
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

30 TGTGCCTTGG GTGGCTTTA

19

(2) INFORMATION FOR SEQ ID NO:26:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: synthetic DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

40 GGCATGGGAA TACAGGTGCA ATTCGGGCA TGGACATTGA CCCTTATAAA

50

WHAT IS CLAIMED IS:

1. A method for detecting the amount of a target nucleic acid sequence which may be present in a test sample comprising the steps of:

- 5 (a) contacting said test sample with means for performing a nucleic acid amplification reaction and:
- 10 (i) two target primer sets, wherein a first primer set represents a first target sequence and a second primer set represents a second target sequence within the genome of the target nucleic acid, and wherein each primer set comprises four oligonucleotide primers of which two are sense primers and the other two are antisense primers,
- 15 (ii) an internal standard (IS) sequence, wherein the IS sequence is substantially derived from a combination of the first target sequence and the second target sequence,
- 20 (iii) an IS primer set, wherein the IS primer set comprises four oligonucleotide primers of which two are derived from the first target sequence and the other two are derived from the second target sequence, and
- 25 (iv) a set of dNTPs,
- under hybridizing conditions such that, for each pair of target oligonucleotide primer sequences or IS oligonucleotide primer sequences which hybridizes to each strand of said target sequences or said IS sequence or its complementary strand, a ligase reaction takes place whereby
- 30 the nucleotide gap between the oligonucleotide primer sequences is filled by the dNTPs in the presence of the target nucleic acid sequence, wherein each of the ligase reactions require the same set of dNTPs, or a subset thereof, to fill the gap; and
- (b) determining the ratio of target amplification products to IS amplification products present in the test sample.

2. The method of claim 1 wherein the amplification reaction comprises thermal cycling between about 15 and about 60 times.

3. The method of claim 1 wherein at least one member of each of said primer sets includes a label.

4. The method of claim 3 wherein said label is indirectly detectable.

5. The method of claim 1 wherein said determining step comprises the steps of:

(a) immobilizing said target amplification products and IS amplification products to a solid phase using capture reagents such that a first capture reagent immobilizes the target amplification products and a second capture reagent immobilizes the IS amplification products; and

(b) detecting a signal generated by the presence of target amplification products or IS amplification products.

6. The method of claim 5 wherein said capture reagents comprise a member of a specific binding pair wherein the binding member specifically binds to a specific binding pair member attached to said amplification product.

7. A method for distinguishing between two different nucleic acid sequences which may be present in a test sample comprising the steps of:

(a) contacting said test sample with means for performing a nucleic acid amplification reaction and:

(i) two target primer sets, wherein a first primer set represents a first target sequence and a second primer set represents a second target sequence within the genome of the target nucleic acid, and wherein each

primer set comprises four oligonucleotide primers of which two are sense primers and the other two are antisense primers,

(ii) an internal standard (IS) sequence, wherein the IS sequence is substantially derived from a combination of the first target sequence and the second target sequence,

(iii) an IS primer set, wherein the IS primer set comprises four oligonucleotide primers of which two are derived from the first target sequence and the other two are derived from the second target sequence, and

(iv) a set of dNTPs,

under hybridizing conditions such that, for each pair of target oligonucleotide primer sequences or IS oligonucleotide primer sequences which hybridizes to each strand of said target sequences or said IS sequence or its complementary strand, a ligase reaction takes place whereby the nucleotide gap between the oligonucleotide primer sequences is filled by the dNTPs in the presence of the target nucleic acid sequence, wherein each of the ligase reactions require the same set of dNTPs, or a subset thereof, to fill the gap; and

(b) determining the ratio of target amplification products to IS amplification products present in the test sample.

8. The method of claim 7, wherein one of the two nucleic acid sequences comprises a mutation or allele of the other nucleic acid sequence.

9. A composition for quantitatively detecting the DNA of hepatitis B virus which may be present in a sample, said composition comprising four oligonucleotide primers of from about 18 to about 25 base pairs having sequences sufficiently complementary to either a first target sequence or second target sequence within the HBV genome, wherein the

target sequence is selected from at least one sequence selected from the group consisting of SEQ ID Nos. 1 and 2 and their complementary strands, and wherein the primers are hybridizable to adjacent portions of the same target strand of HBV DNA.

5

10. The composition according to claim 9, wherein the oligonucleotide primers comprise SEQ ID Nos. 3, 4, 5 and 6.

11. A composition for distinguishing between the wildtype and mutant DNA of hepatitis B comprising codon 145 of the HBV S-gene, said composition comprising four oligonucleotide primers of from about 18 to about 25 base pairs having sequences sufficiently complementary to either a first target sequence or second target sequence within the HBV S-gene, wherein the target sequence is selected from at least one sequence selected from the group consisting of SEQ ID Nos. 12 and 13 and their complementary strands, and wherein the primers are hybridizable to adjacent portions of the same target strand of HBV DNA.

12. The composition according to claim 11, wherein the oligonucleotide primers comprise SEQ ID Nos. 14, 15, 16, 17 and 18.

13. A composition for distinguishing between the wildtype and mutant DNA of hepatitis B comprising codon 28 of the HBV precore antigen gene, said composition comprising four oligonucleotide primers of from about 18 to about 25 base pairs having sequences sufficiently complementary to either a first target sequence or second target sequence within the HBV pre-core antigen gene, wherein the target sequence is selected from at least one sequence selected from the group consisting of SEQ ID Nos. 19 and 20 and their complementary strands, and wherein the primers are hybridizable to adjacent portions of the same target strand of HBV DNA.

14. The composition according to claim 13, wherein the

oligonucleotide primers comprise SEQ ID Nos. 21, 22, 23, 24 and 25.

15. A kit for quantitatively detecting hepatitis B virus comprising a composition comprising oligonucleotide primer sets according to claim 9 or 10.

16. A kit for distinguishing between the wildtype and mutant DNA of hepatitis B comprising codon 145 of the HBV S-gene comprising a composition comprising oligonucleotide primer sets according to claim 11 or 12.

15 17. A kit for distinguishing between the wildtype and mutant DNA of hepatitis B comprising codon 28 of the HBV precore antigen gene comprising a composition comprising oligonucleotide primer sets according to claim 13 or 14.

18. The kit according to claim 16 further comprising a composition comprising oligonucleotide primer sets according to claim 13 or 14.

INTERNATIONAL SEARCH REPORT

In national Application No
PCT/US 96/08429

A. CLASSIFICATION OF SUBJECT MATTER
IPC $\frac{C}{6}$ C12Q1/68 C12Q1/70 C12P19/34 C07H21/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HUMAN MUTATION RESEARCH, vol. 6, no. 2, 1995, pages 144-51, XP000600992 FANG P ET AL: "Simutaneous analysis of mutant and normal alleles for multiple cystic fibrosis mutations by the ligase chain reaction" see the whole document	9-18
A	---	1-8
X	WO,A,94 08047 (ABBOTT LABORATORIES) 14 April 1994	9-18
A	see page 9, line 24 - page 25, line 10 ---	1-8
X	WO,A,93 20227 (ABBOTT LABORATORIES) 14 October 1993	9-18
A	see page 8, line 32 - page 9, line 11 ---	1-8
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 September 1996

Date of mailing of the international search report

27.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

Inventor's Application No
PCT/US 96/08429

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 473 155 (ABBOTT LABORATORIES) 4 March 1992	9-18
A	see page 9, line 30 - line 44; table 1 ---	1-8
Y	WO,A,95 02690 (ABBOTT LABORATORIES) 26 January 1995 see the whole document ---	9-18
Y	EP,A,0 593 789 (SUMITOMO METAL INDUSTRIES) 27 April 1994 see the whole document ---	9-18
Y	WO,A,93 02215 (ROYAL FREE HOSPITAL SCHOOL OF MEDICINE) 4 February 1993	9-18
A	see the whole document ---	1-8
A	BIOTECHNIQUES, vol. 16, no. 1, 1994, pages 114-21, XP000420684 GOSWAMI B ET AL: "Competitor template RNA for detection and quantitation of hepatitis A virus by PCR" see the whole document -----	1-8

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/08429

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9408047	14-04-94	AU-A- 4848393	26-04-94
WO-A-9320227	14-10-93	AU-A- 3942993	08-11-93
		CA-A- 2133220	14-10-93
		EP-A- 0633944	18-01-95
		JP-T- 7505293	15-06-95
EP-A-473155	04-03-92	AU-A- 8344591	05-03-92
		CA-A- 2049879	01-03-92
		JP-A- 4229200	18-08-92
WO-A-9502690	26-01-95	AU-A- 7326494	13-02-95
EP-A-593789	27-04-94	JP-A- 5308999	22-11-93
		WO-A- 9323567	25-11-93
WO-A-9302215	04-02-93	NONE	